Share on StockTwits

Hikma Pharmaceuticals Plc (LON:HIK)‘s stock had its “overweight” rating reaffirmed by analysts at Barclays in a research report issued to clients and investors on Monday. They currently have a GBX 1,890 ($31.78) target price on the stock. Barclays’ price objective suggests a potential upside of 9.57% from the company’s current price.

A number of other firms have also recently commented on HIK. Analysts at Jefferies Group raised their price target on shares of Hikma Pharmaceuticals Plc from GBX 1,500 ($25.22) to GBX 1,600 ($26.90) in a research note on Thursday, May 15th. They now have a “hold” rating on the stock. Separately, analysts at Citigroup Inc. reiterated a “buy” rating on shares of Hikma Pharmaceuticals Plc in a research note on Wednesday, May 14th. They now have a GBX 1,800 ($30.26) price target on the stock. Finally, analysts at Citigroup Inc. reiterated a “buy” rating on shares of Hikma Pharmaceuticals Plc in a research note on Thursday, May 1st. They now have a GBX 1,800 ($30.26) price target on the stock. Six investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of GBX 1,617.14 ($27.19).

Shares of Hikma Pharmaceuticals Plc (LON:HIK) opened at 1721.9999 on Monday. Hikma Pharmaceuticals Plc has a one year low of GBX 903.50 and a one year high of GBX 1721.9999. The stock’s 50-day moving average is GBX 1606.31 and its 200-day moving average is GBX 1412.. The company’s market cap is £3.405 billion.

Hikma Pharmaceuticals PLC is engaged in the development, manufacture and marketing of a range of generic and in-licensed pharmaceutical products in solid, semi-solid, liquid and injectable final dosage forms.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.